Anika Historical Financial Ratios
ANIK Stock | USD 16.25 0.02 0.12% |
Anika Therapeutics is presently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 1.73 or Days Sales Outstanding of 54.36 will help investors to properly organize and evaluate Anika Therapeutics financial condition quickly.
Anika |
About Anika Financial Ratios Analysis
Anika TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Anika Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Anika financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Anika Therapeutics history.
Anika Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Anika Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Anika Therapeutics sales, a figure that is much harder to manipulate than other Anika Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Tangible Asset Value
The total value of a company's physical, tangible assets, excluding intangible assets like patents and trademarks.Most ratios from Anika Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Anika Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.At this time, Anika Therapeutics' EV To Sales is quite stable compared to the past year. Inventory Turnover is expected to rise to 1.48 this year, although the value of Operating Cash Flow Per Share is projected to rise to (0.12).
2021 | 2022 | 2023 | 2024 (projected) | |
Days Sales Outstanding | 73.7 | 80.9 | 78.76 | 54.36 |
PTB Ratio | 1.8 | 1.51 | 1.56 | 1.73 |
Anika Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Anika Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Anika Therapeutics fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 6.39 | 4.93 | 3.49 | 2.76 | 1.99 | 3.33 | |
Ptb Ratio | 2.54 | 2.36 | 1.8 | 1.51 | 1.56 | 1.73 | |
Days Sales Outstanding | 73.5 | 67.43 | 73.7 | 80.9 | 78.76 | 54.36 | |
Book Value Per Share | 20.42 | 19.15 | 19.94 | 19.61 | 14.48 | 15.21 | |
Free Cash Flow Yield | 0.0467 | 0.0178 | 0.006306 | (0.007139) | (0.0217) | (0.0228) | |
Stock Based Compensation To Revenue | 0.0531 | 0.0413 | 0.075 | 0.0916 | 0.0915 | 0.0869 | |
Capex To Depreciation | 0.79 | 0.47 | 0.12 | 0.36 | 0.52 | 0.38 | |
Pb Ratio | 2.54 | 2.36 | 1.8 | 1.51 | 1.56 | 1.73 | |
Ev To Sales | 3.75 | 5.2 | 4.36 | 2.98 | 2.4 | 1.73 | |
Free Cash Flow Per Share | 2.42 | 0.8 | 0.23 | (0.21) | (0.49) | (0.47) | |
Roic | 0.0894 | (0.0445) | (0.11) | (0.0538) | (0.4) | (0.38) | |
Inventory Turnover | 1.31 | 1.33 | 1.8 | 1.58 | 1.37 | 1.48 | |
Net Income Per Share | 1.93 | (1.69) | 0.29 | (1.02) | (5.64) | (5.36) | |
Days Of Inventory On Hand | 279.27 | 274.56 | 202.67 | 231.63 | 266.32 | 285.53 | |
Payables Turnover | 7.5 | 6.84 | 8.5 | 6.91 | 6.45 | 6.22 | |
Capex To Revenue | 0.0247 | 0.0125 | 0.0348 | 0.0479 | 0.0326 | 0.0309 | |
Cash Per Share | 13.1 | 6.91 | 6.55 | 5.93 | 4.97 | 3.5 | |
Pocfratio | 19.79 | 49.27 | 61.45 | 97.76 | (185.74) | (176.45) | |
Capex To Operating Cash Flow | 0.0764 | 0.12 | 0.61 | 1.7 | (3.04) | (2.88) | |
Pfcf Ratio | 21.42 | 56.28 | 158.57 | (140.07) | (46.03) | (43.73) | |
Days Payables Outstanding | 48.65 | 53.38 | 42.96 | 52.86 | 56.61 | 80.78 | |
Income Quality | 1.36 | (0.54) | 2.03 | (0.3) | 0.0216 | 0.0205 | |
Roe | 0.0943 | (0.088) | 0.0144 | (0.052) | (0.39) | (0.37) | |
Ev To Operating Cash Flow | 16.11 | 43.53 | 52.5 | 85.18 | (161.23) | (153.17) | |
Pe Ratio | 26.93 | (26.84) | 124.82 | (29.01) | (4.02) | (3.82) | |
Return On Tangible Assets | 0.0862 | (0.0901) | 0.0161 | (0.0556) | (0.32) | (0.3) | |
Ev To Free Cash Flow | 17.44 | 49.73 | 135.48 | (122.06) | (39.95) | (37.96) | |
Earnings Yield | 0.0371 | (0.0373) | 0.008012 | (0.0345) | (0.25) | (0.24) | |
Intangibles To Total Assets | 0.0462 | 0.27 | 0.26 | 0.23 | 0.0451 | 0.0428 | |
Net Debt To E B I T D A | (3.97) | 5.84 | (28.74) | 11.28 | 3.9 | 4.1 | |
Current Ratio | 14.48 | 4.81 | 5.66 | 6.07 | 5.26 | 7.0 | |
Tangible Book Value Per Share | 19.34 | 12.15 | 13.67 | 13.98 | 13.65 | 14.33 | |
Receivables Turnover | 4.97 | 5.41 | 4.95 | 4.51 | 4.63 | 7.3 | |
Graham Number | 29.75 | 26.96 | 11.35 | 21.22 | 42.87 | 45.02 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (6.64) | Revenue Per Share 11.139 | Quarterly Revenue Growth (0.07) | Return On Assets (0.04) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.